CA3226269A1 - Asgpr cell surface receptor binding compounds and conjugates - Google Patents
Asgpr cell surface receptor binding compounds and conjugates Download PDFInfo
- Publication number
- CA3226269A1 CA3226269A1 CA3226269A CA3226269A CA3226269A1 CA 3226269 A1 CA3226269 A1 CA 3226269A1 CA 3226269 A CA3226269 A CA 3226269A CA 3226269 A CA3226269 A CA 3226269A CA 3226269 A1 CA3226269 A1 CA 3226269A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- optionally substituted
- linker
- antibody
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163221918P | 2021-07-14 | 2021-07-14 | |
| US63/221,918 | 2021-07-14 | ||
| PCT/US2022/037227 WO2023288033A1 (en) | 2021-07-14 | 2022-07-14 | Asgpr cell surface receptor binding compounds and conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3226269A1 true CA3226269A1 (en) | 2023-01-19 |
Family
ID=82786913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3226269A Pending CA3226269A1 (en) | 2021-07-14 | 2022-07-14 | Asgpr cell surface receptor binding compounds and conjugates |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12258332B2 (https=) |
| EP (1) | EP4370157A1 (https=) |
| JP (1) | JP2024524614A (https=) |
| KR (1) | KR20240036604A (https=) |
| CN (1) | CN117957020A (https=) |
| AU (1) | AU2022310356A1 (https=) |
| CA (1) | CA3226269A1 (https=) |
| WO (1) | WO2023288033A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021155317A1 (en) | 2020-01-31 | 2021-08-05 | Avilar Therapeutics, Inc. | Asgpr-binding compounds for the degradation of extracellular proteins |
| EP4651902A2 (en) | 2023-01-18 | 2025-11-26 | Lycia Therapeutics, Inc. | Asgpr binding compounds and conjugates |
| JP2026503462A (ja) | 2023-01-18 | 2026-01-29 | ライシア セラピューティクス， インコーポレイテッド | 自己抗体の分解のためのリソソーム標的化二官能性分子 |
| CN120882430A (zh) | 2023-01-18 | 2025-10-31 | 利西亚治疗公司 | 循环溶酶体靶向抗体缀合物 |
| WO2024167900A2 (en) * | 2023-02-06 | 2024-08-15 | Biohaven Therapeutics Ltd. | Bifunctional molecules to target degradation of tumor necrosis factor |
| WO2025035040A1 (en) | 2023-08-09 | 2025-02-13 | Lycia Therapeutics, Inc. | Lysosomal targeting bifunctional molecules for degradation of muscle-specific kinase autoantibodies |
| CN116854754B (zh) | 2023-09-01 | 2023-12-12 | 北京悦康科创医药科技股份有限公司 | 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物 |
| TW202516008A (zh) * | 2023-09-27 | 2025-04-16 | 大陸商上海拓界生物醫藥科技有限公司 | 含三唑基化合物、製備方法及用途 |
| WO2025199666A1 (en) * | 2024-03-25 | 2025-10-02 | Canwell Biotech Limited | Multivalent linkers for high loading antibody-drug conjugates, and compositions and methods thereof |
| TW202602932A (zh) | 2024-03-28 | 2026-01-16 | 美商萊西亞醫療公司 | 用於降解甲狀腺刺激荷爾蒙受體自體抗體之胞溶體靶向雙功能分子 |
| WO2025252118A1 (zh) * | 2024-06-06 | 2025-12-11 | 苏州瑞博生物技术股份有限公司 | 整联蛋白αvβ6特异性配体化合物、缀合物、药物组合物及其用途 |
| WO2026015664A1 (en) | 2024-07-10 | 2026-01-15 | Lycia Therapeutics, Inc. | Cycling lysosomal targeting chimeras targeting immunoglobulin e (ige) |
| CN120285222B (zh) * | 2025-04-15 | 2025-11-18 | 上海交通大学 | 一种靶向肝脏的药物靶向递送系统及其治疗和/或辅助治疗代谢相关脂肪性肝病的药物 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991014438A1 (en) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| AU2752892A (en) | 1991-09-26 | 1993-04-27 | Oklahoma Medical Research Foundation | Fusion proteins targeted to lysosomes, for the treatment of aids |
| GB9323429D0 (en) | 1993-11-12 | 1994-01-05 | Wellcome Found | Therapy |
| DK129293D0 (da) | 1993-11-16 | 1993-11-16 | Carlsberg Lab | Carbonhydratholdige forbindelser, der kan binde sig til carbonhydratbindende receptorer |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US20020168761A1 (en) | 2000-01-24 | 2002-11-14 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| AU2662999A (en) | 1998-02-09 | 1999-08-23 | Genzyme Corporation | Nucleic acid delivery vehicles |
| US6093382A (en) | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| AU770340B2 (en) | 1998-10-08 | 2004-02-19 | Biorion Technologies B.V. | Peptide-based carrier devices for stellate cells |
| US6426208B1 (en) | 1999-11-12 | 2002-07-30 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| EP1242824A2 (en) | 1999-12-30 | 2002-09-25 | 7TM Pharma | Screening using biological target molecules with metal-ion binding sites |
| US20040009907A1 (en) | 2001-02-26 | 2004-01-15 | Alsobrook John P. | Proteins and nucleic acids encoding same |
| EP1284752A4 (en) | 2000-04-26 | 2004-08-18 | Elusys Therapeutics Inc | BISPECIFIC MOLECULES AND USES THEREOF |
| DE10138935B4 (de) * | 2000-08-11 | 2007-08-02 | Kotobuki Pharmaceutical Co., Ltd, , Hanishina | Synthetische Verbindungen vom Nicht-Mucintyp oder ihre mit einem Träger konjugierten Verbindungen, unter deren Verwendung hergestellte monoclonale Antikörper, diese umfassende Antitumormittel Immunstimulantien und Mittel gegen das humane Immundefizienzvirus |
| NZ524980A (en) | 2000-09-01 | 2005-10-28 | Biogen Idec Inc | Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications |
| EP1385538B1 (en) | 2001-04-05 | 2013-01-30 | The Johns Hopkins University | Chimeric Vaccines comprising the lumenal domain of LAMP-1 or LAMP-2 |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| US20030049203A1 (en) | 2001-08-31 | 2003-03-13 | Elmaleh David R. | Targeted nucleic acid constructs and uses related thereto |
| ES2411007T3 (es) | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| JP4801348B2 (ja) | 2002-05-06 | 2011-10-26 | エンドサイト，インコーポレイテッド | ビタミンを標的とした造影剤 |
| US20050191309A1 (en) | 2002-05-06 | 2005-09-01 | Kakkis Emil D. | Induction of antigen specific immunologic tolerance |
| US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| ES2330004T3 (es) | 2003-05-20 | 2009-12-03 | Pharmaxis Pty Ltd. | Compuestos de manosa-6-fosfonato para el tratamiento de enfermedades inflamatorias. |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| GB0423405D0 (en) | 2004-10-21 | 2004-11-24 | Novartis Ag | Organic compounds |
| EP1904183B1 (en) | 2005-07-05 | 2014-10-15 | Purdue Research Foundation | Pharmaceutical composition for the treatment of osteoarthritis |
| EP1745802A1 (en) | 2005-07-20 | 2007-01-24 | Kreatech Biotechnology B.V. | Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes |
| WO2008020827A2 (en) | 2005-08-01 | 2008-02-21 | Biogen Idec Ma Inc. | Altered polypeptides, immunoconjugates thereof, and methods related thereto |
| US20070104648A1 (en) | 2005-11-09 | 2007-05-10 | Glyconix Corporation | Compositions, methods of preparing amino acids, and nuclear magnetic resonance spectroscopy |
| AU2007234698B2 (en) | 2006-04-07 | 2013-08-01 | The Board Of Regents Of The University Of Texas System | Methods and compositions related to adenoassociated virus-phage particles |
| US20080057072A1 (en) | 2006-08-31 | 2008-03-06 | Alcon Manufacturing, Ltd. | Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders |
| RU2500685C2 (ru) | 2006-11-10 | 2013-12-10 | Кара Терапеутикс, Инк | Синтетические пептидные амиды |
| WO2008089339A2 (en) | 2007-01-18 | 2008-07-24 | Genzyme Corporation | Oligosaccharide conjugates for cellular targeting |
| CA2690627C (en) | 2007-06-15 | 2014-12-02 | Genelux Corporation | Microorganisms for imaging and/or treatment of tumors |
| JP5366940B2 (ja) | 2008-05-08 | 2013-12-11 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
| ES3029483T3 (en) | 2008-09-17 | 2025-06-24 | Endocyte Inc | Folate receptor binding conjugates of antifolates |
| GB0817891D0 (en) | 2008-09-30 | 2008-11-05 | Medical Res Council | Antibodies against il-25 |
| CN102369023A (zh) | 2008-12-16 | 2012-03-07 | 建新公司 | 寡糖-蛋白缀合物 |
| US20110275576A1 (en) * | 2009-01-06 | 2011-11-10 | Utah State University | Carbohydrate-Cyclopamine Conjugates as Anticancer Agents |
| KR101722961B1 (ko) | 2009-02-11 | 2017-04-04 | 알부메딕스 에이/에스 | 알부민 변이체 및 접합체 |
| CA2748889A1 (en) | 2009-03-18 | 2010-09-23 | Armagen Technologies, Inc. | Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |
| US8557783B2 (en) | 2009-04-28 | 2013-10-15 | Pharmaxis Pty Limited | Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders |
| US8962573B2 (en) | 2009-07-03 | 2015-02-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Compounds targeting the cation-independent mannose 6-phosphate receptor |
| EP2480235A4 (en) | 2009-09-24 | 2013-05-08 | Univ Louisville Res Found | NEW IODO-PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ILLNESSES AND SUFFERING IN CONNECTION WITH THE MACROPHAGE MIGRATION-INHIBITING FACTOR |
| FR2952372B1 (fr) | 2009-11-10 | 2012-03-23 | Centre Nat Rech Scient | Nouveaux derives de mannopyranoside ayant une activite anticancereuse |
| EP2343081A1 (en) | 2009-12-31 | 2011-07-13 | Rijksuniversiteit Groningen | Interferon analogs |
| TWI622402B (zh) | 2010-02-24 | 2018-05-01 | 免疫遺傳股份有限公司 | 葉酸受體１抗體類和免疫共軛物類及彼等之用途 |
| FR2960153B1 (fr) | 2010-05-20 | 2012-08-17 | Centre Nat Rech Scient | Nouveaux bras autoreactifs et prodrogues les comprenant |
| RU2012157167A (ru) | 2010-07-12 | 2014-08-20 | КовЭкс Текнолоджиз Айэлэнд Лимитед | Полифункциональные антительные конъюгаты |
| US20120121592A1 (en) | 2010-10-13 | 2012-05-17 | Baylor Research Institute | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells |
| HRP20180291T1 (hr) | 2011-05-27 | 2018-03-23 | Amicus Therapeutics, Inc. | Postupci za sparivanje ciljajućeg peptida na rekombinantne lizosomalne enzime za poboljšano liječenje lizosomskih bolesti nakupljanja |
| EP2825553B1 (en) | 2012-03-14 | 2018-07-25 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
| CA3140358A1 (en) | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| WO2014082080A2 (en) | 2012-11-26 | 2014-05-30 | Callidus Biopharma, Inc. | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases |
| WO2014089209A2 (en) | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
| AU2014218854B2 (en) | 2013-02-20 | 2019-01-24 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Pompe disease |
| ES2824026T3 (es) | 2013-05-03 | 2021-05-11 | Univ Yale | Compuestos miméticos de anticuerpos sintéticos (SyAM) dirigidos al cáncer, especialmente cáncer de próstata |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| WO2015042447A1 (en) * | 2013-09-20 | 2015-03-26 | Isis Pharmaceuticals, Inc. | Targeted therapeutic nucleosides and their use |
| EP3610884B1 (en) | 2013-11-06 | 2021-08-18 | Merck Sharp & Dohme Corp. | Peptide containing conjugates for dual molecular delivery of oligonucleotides |
| SG11201606761RA (en) * | 2014-02-21 | 2016-09-29 | Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto | Glycotargeting therapeutics |
| WO2015143091A1 (en) | 2014-03-19 | 2015-09-24 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| PL3145934T3 (pl) | 2014-05-19 | 2021-08-16 | Pfizer Inc. | Podstawione związki 6,8-dioksabicyklo[3.2.1]oktano-2,3-diolu jako środki kierujące do ASGPR |
| WO2015191934A2 (en) | 2014-06-11 | 2015-12-17 | Abbvie Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases |
| EP3185889B1 (en) | 2014-08-11 | 2020-07-15 | Shire Human Genetic Therapies, Inc. | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes |
| US20170290806A1 (en) | 2014-09-08 | 2017-10-12 | Temple University-Of The Commonwealth System Of Higher Education | PCSK9 Inhibitors and Methods of Use Thereof |
| CA3205824A1 (en) | 2014-10-09 | 2016-04-14 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
| US20160166679A1 (en) | 2014-12-12 | 2016-06-16 | Purdue Research Foundation | Method of treatment using folate conjugates and tyrosine kinase inhibitors |
| IL296285A (en) | 2015-07-06 | 2022-11-01 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| JP7007261B2 (ja) | 2015-08-20 | 2022-01-24 | アルブミディクス リミティド | アルブミン変異体及びコンジュゲート |
| FR3041345B1 (fr) | 2015-09-18 | 2019-06-14 | Nanomedsyn | Composes polysaccharides multi-fonctionnalises et leur utilisation pour cibler le recepteur du mannose 6-phosphate cation-independant |
| CA3289997A1 (en) | 2015-09-20 | 2026-03-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal Antibodies Specific for Fibroblast Growth Factor Receptor 4 (FGFR4) and Methods of Their Use |
| EP3356415B1 (en) | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
| EP3384034B1 (en) | 2015-12-02 | 2020-07-08 | The Board of Trustees of the Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism |
| DK3386534T3 (da) | 2015-12-08 | 2020-11-30 | Regeneron Pharma | Sammensætninger og fremgangsmåder til internalisering af enzymer |
| KR20260018979A (ko) | 2016-02-05 | 2026-02-09 | 젠맵 에이/에스 | 개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자 |
| EP3411484B1 (en) | 2016-02-05 | 2023-10-04 | Emory University | Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid |
| WO2017212019A1 (en) | 2016-06-09 | 2017-12-14 | Centre National De La Recherche Scientifique (Cnrs) | Raav with chemically modified capsid |
| KR102085798B1 (ko) | 2016-12-28 | 2020-03-06 | 주식회사 인투셀 | 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물 |
| DK3635009T3 (da) | 2017-06-07 | 2026-03-30 | Regeneron Pharma | Sammensætninger og fremgangsmåder til internalisering af enzymer |
| EP3773727A4 (en) | 2018-04-09 | 2022-05-04 | Yale University | BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS |
| WO2019199621A1 (en) | 2018-04-09 | 2019-10-17 | Yale University | Bi-functional molecules to degrade circulating proteins |
| JP2022506517A (ja) * | 2018-11-02 | 2022-01-17 | アルブータス・バイオファーマー・コーポレイション | 標的指向化二価結合体 |
| AU2019404061A1 (en) | 2018-12-19 | 2021-07-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules for lysosomal targeting and related compositions and methods |
| GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| GB201908108D0 (en) | 2019-06-06 | 2019-07-24 | King S College London | Product |
| EP3986936A4 (en) | 2019-06-21 | 2023-03-15 | Single Cell Technology, Inc. | ANTI-TIGIT ANTIBODIES |
| EP3997214B1 (en) | 2019-07-11 | 2023-08-02 | Centre National de la Recherche Scientifique | Chemically-modified adeno-associated virus |
| EP4041262A4 (en) | 2019-10-10 | 2024-03-13 | Yale University | Targeted bifunctional degraders |
| KR20220099963A (ko) | 2019-10-10 | 2022-07-14 | 예일 유니버시티 | 세포 수용체를 통한 분자 분해제로서의 조작된 항체 |
| US20210189392A1 (en) * | 2019-12-12 | 2021-06-24 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| US20230158155A1 (en) | 2020-01-10 | 2023-05-25 | Lycia Therapeutics, Inc. | Cell Surface Receptor Binding Compounds and Conjugates |
| WO2021155317A1 (en) | 2020-01-31 | 2021-08-05 | Avilar Therapeutics, Inc. | Asgpr-binding compounds for the degradation of extracellular proteins |
| WO2021156792A1 (en) | 2020-02-07 | 2021-08-12 | Novartis Ag | Targeted plasma protein degradation |
| WO2021262693A1 (en) | 2020-06-22 | 2021-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methotrexate analogs and methods of use |
| EP4171659A4 (en) | 2020-06-24 | 2025-04-09 | Lycia Therapeutics, Inc. | BIFUNCTIONAL BRIDGE COMPOSITIONS FOR VIRAL TRANSDUCTION |
| EP4171658A4 (en) | 2020-06-24 | 2025-04-09 | Lycia Therapeutics, Inc. | Modified viral compositions for viral transduction |
| CN113943288A (zh) | 2020-07-17 | 2022-01-18 | 微境生物医药科技(上海)有限公司 | 5,6-二氢吡嗪并[2,3-c]异喹啉化合物 |
| WO2022035997A1 (en) | 2020-08-11 | 2022-02-17 | Avilar Therapeutics, Inc. | In vivo assembly of asgpr binding therapeutics |
| EP4274619A4 (en) | 2021-01-08 | 2025-09-24 | Lycia Therapeutics Inc | BIFUNCTIONAL FOLATE RECEPTOR-BINDING COMPOUNDS |
| EP4281115A1 (en) | 2021-01-19 | 2023-11-29 | Novartis AG | Degradation of extracellular targets |
| AU2022222778A1 (en) | 2021-02-22 | 2023-08-31 | Yale University | Targeted bifunctional degraders and methods using same |
| WO2022192478A1 (en) | 2021-03-10 | 2022-09-15 | Biohaven Therapeutics Ltd. | Bifunctional degraders of galactose-deficient immunoglobulins |
| KR20240017423A (ko) | 2021-05-03 | 2024-02-07 | 아빌라 테라퓨틱스, 인크. | 이뮤노글로불린 및 다른 단백질의 분해를 위한 강력한 asgpr-결합 화합물 |
| WO2022271981A2 (en) | 2021-06-23 | 2022-12-29 | Lycia Therapeutics, Inc. | Bifunctional compounds containing igf-2 polypeptides |
| US20250127913A1 (en) | 2021-06-24 | 2025-04-24 | Lycia Therapeutics, Inc. | Bifunctional folate receptor binding compounds |
| AU2022310346A1 (en) | 2021-07-14 | 2024-01-25 | Lycia Therapeutics, Inc. | M6pr cell surface receptor binding compounds and conjugates |
| WO2023009554A1 (en) | 2021-07-26 | 2023-02-02 | Avilar Therapeutics, Inc. | Methods to reduce adverse effects of gene or biologics therapy |
| WO2023028590A1 (en) | 2021-08-27 | 2023-03-02 | Yale University | Molecular degraders of extracellular proteins |
| JP2024532362A (ja) | 2021-08-27 | 2024-09-05 | イエール ユニバーシティ | 細胞外タンパク質の分子分解誘導剤 |
| WO2023028338A2 (en) | 2021-08-27 | 2023-03-02 | Avilar Therapeutics, Inc. | Mannose 6-phosphate or asgpr receptor binding compounds for the degradation of extracellular proteins |
| IL315579A (en) | 2022-03-15 | 2024-11-01 | Univ Yale | Small bifunctional compounds to target selective degradation of circulating proteins |
| EP4611818A2 (en) | 2022-11-03 | 2025-09-10 | Avilar Therapeutics, Inc. | Asgpr-binding heterobifunctional compounds for the degradation of immunoglobulins |
-
2022
- 2022-07-14 EP EP22750971.8A patent/EP4370157A1/en active Pending
- 2022-07-14 JP JP2024501119A patent/JP2024524614A/ja active Pending
- 2022-07-14 CN CN202280061489.6A patent/CN117957020A/zh active Pending
- 2022-07-14 WO PCT/US2022/037227 patent/WO2023288033A1/en not_active Ceased
- 2022-07-14 CA CA3226269A patent/CA3226269A1/en active Pending
- 2022-07-14 AU AU2022310356A patent/AU2022310356A1/en active Pending
- 2022-07-14 KR KR1020247004826A patent/KR20240036604A/ko active Pending
-
2023
- 2023-04-14 US US18/301,025 patent/US12258332B2/en active Active
-
2024
- 2024-12-09 US US18/974,654 patent/US20250101007A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022310356A1 (en) | 2024-01-25 |
| WO2023288033A8 (en) | 2023-06-22 |
| CN117957020A (zh) | 2024-04-30 |
| US20250101007A1 (en) | 2025-03-27 |
| EP4370157A1 (en) | 2024-05-22 |
| JP2024524614A (ja) | 2024-07-05 |
| US12258332B2 (en) | 2025-03-25 |
| US20230250091A1 (en) | 2023-08-10 |
| KR20240036604A (ko) | 2024-03-20 |
| WO2023288033A1 (en) | 2023-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3226269A1 (en) | Asgpr cell surface receptor binding compounds and conjugates | |
| US20240335544A1 (en) | M6pr cell surface receptor binding compounds and conjugates | |
| US20230158155A1 (en) | Cell Surface Receptor Binding Compounds and Conjugates | |
| AU2018269568B2 (en) | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | |
| BR112020013492A2 (pt) | Esteroides e conjugados de anticorpo dos mesmos | |
| CN113905767A (zh) | 无痕连接体及其蛋白质偶联物 | |
| KR20160142885A (ko) | 친화성 약제 컨쥬게이트 | |
| JP2026503463A (ja) | Ａｓｇｐｒ結合化合物およびコンジュゲート | |
| JP4722484B2 (ja) | グリセロール誘導体 | |
| JP2026503461A (ja) | サイクリングリソソーム標的化抗体コンジュゲート | |
| TW202406574A (zh) | 一種包含親水性糖結構的配體-藥物偶聯物 | |
| WO2024155748A1 (en) | M6pr binding compounds and conjugates | |
| TW202610689A (zh) | 靶向免疫球蛋白ｅ（ｉｇｅ）之循環溶酶體靶向嵌合體 | |
| WO2026065268A1 (en) | Novel conjugates for protein degradation, compositions comprising the same, and methods of using the same | |
| JP2025526869A (ja) | アントラサイクリン及びそのコンジュゲート | |
| CN120513102A (zh) | 一种抗体药物偶联物及其制备方法和用途 | |
| TW202506691A (zh) | Ｓｔｉｎｇ促效劑化合物及其結合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20250320 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250520 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250520 |